Nektar Therapeutics NKTR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $55.63M+0.7% | $55.23M-11.8% | $62.6M-16.5% | $74.93M-14.1% | $87.25M-11.4% | ||
| —— | $55.23M+1.1% | $54.62M-12.6% | $62.52M-4.0% | $65.1M-3.9% | ||
| $122.53M+4.4% | $117.33M+0.8% | $116.36M-6.3% | $124.14M+0.1% | $123.98M+2.5% | ||
| $57.77M-15.9% | $68.67M-8.0% | $74.62M-3.7% | $77.51M-4.2% | $80.95M+5.5% | ||
| $190.25M-2.6% | $195.33M+21.6% | $160.69M-8.5% | $175.7M-12.8% | $201.55M-1.0% | ||
| -$134.62M+3.9% | -$140.1M— | —— | —— | —— | ||
| -242%+11.7pp | -253.7%— | —— | —— | —— | ||
| $11.81M+13.1% | $10.44M-1.6% | $10.6M-5.5% | $11.22M-14.7% | $13.15M-9.3% | ||
| -$17.59M-14.3% | -$15.39M+2.0% | -$15.69M-4.3% | -$15.05M-4.3% | -$14.43M-3.0% | ||
| -$6.02M+31.1% | -$8.73M-18.2% | -$7.38M-7.8% | -$6.85M-53.5% | -$4.46M— | ||
| -$152.21M+2.1% | -$155.49M-28.7% | -$120.79M+1.7% | -$122.81M+9.5% | -$135.73M-7.6% | ||
| —— | —— | -$428K-10.9% | -$386K-154% | -$152K+36.4% | ||
| -$158.1M+3.6% | -$164.08M-28.2% | -$128M+1.2% | -$129.53M+7.7% | -$140.3M-11.2% | ||
| -284.2%+12.9pp | -297.1%-92.6pp | -204.5%-31.6pp | -172.9%-12.1pp | -160.8%-32.6pp | ||
| -$8.23+17.9% | -$10.03+4.6% | -$10.51+7.0% | -$11.30+6.7% | -$12.11-39.5% | ||
| -$8.23+17.9% | -$10.03+4.6% | -$10.51+7.0% | -$11.30+6.7% | -$12.11-39.5% | ||
| 74.6M+16.7% | 64M+5.2% | 60.8M+9.0% | 55.8M+0.3% | 55.6M-76.5% | ||
| 74.6M+16.7% | 64M+5.2% | 60.8M+9.0% | 55.8M+0.3% | 55.6M-76.5% | ||
| —— | $0-100% | $10.1M-50.0% | $20.2M-33.3% | $30.29M-25.0% | ||
| $29.15M+11.3% | $26.18M-1.4% | $26.57M+0.1% | $26.54M-3.7% | $27.56M-2.0% | ||
| -$152.08M+2.1% | -$155.35M-28.8% | -$120.62M+1.7% | -$122.69M+9.7% | -$135.84M-7.6% | ||
| —— | —— | $270K-0.4% | $271K+1,184% | -$25K+93.6% | ||
| $9.96M+6.7% | $9.33M+341% | $2.12M+4.6% | $2.02M-86.4% | $14.86M-5.1% | ||
| $55.63M+0.7% | $55.23M-11.8% | $62.6M-16.5% | $74.93M-14.1% | $87.25M-11.4% | ||
| -$134.62M+3.9% | -$140.1M-24.6% | -$112.44M+2.3% | -$115.11M+10.5% | -$128.65M-7.6% | ||
| -$133.87M+3.7% | -$139.08M-25.0% | -$111.27M+1.7% | -$113.15M+9.8% | -$125.44M-8.9% | ||
| -$133.87M+3.7% | -$139.08M-25.0% | -$111.27M+1.7% | -$113.15M+9.8% | -$125.44M-8.9% | ||
| -240.6%+11.2pp | -251.8%-74.1pp | -177.7%-26.8pp | -151%-7.2pp | -143.8%-26.8pp | ||
| -$134.62M+3.9% | -$140.1M-24.6% | -$112.44M+2.3% | -$115.11M+10.5% | -$128.65M-7.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Nektar Therapeutics's profit margins?
- Gross margin is 100.0% and operating margin is -242.0%, with a -284.2% net margin.
- Where does Nektar Therapeutics's income statement data come from?
- Every line is extracted from Nektar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.